COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
Formycon's FYB201/Ranivisio® is Europe's First Ranibizumab Biosimilar available in Pre-filled Syringe, offering improved handling, accuracy, and convenience for applicants. Teva to commercialize across Europe -
-
-
COMMUNIQUÉ DE PRESSE
Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Actor Pharmaceuticals and Megalabs to commercialize Formycon's Eylea biosimilar FYB203 in Australia and Latin America. Partnership agreements include upfront payments and royalties -
-
-
COMMUNIQUÉ DE PRESSE
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron. Commercial launch expected in Q4/2026
